Search filters
Filters
Clear AllPhase
-
183
-
156
-
2
-
194
-
1
-
148
-
17
-
396
Age
-
1237
-
588
Gender
-
29
-
49
-
3
-
1162
Virtual Trials
-
1237
-
6
New Trials
-
3
-
1240
Loading...
Found 1243 All Conditions trials
A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
PURPOSE/DESCRIPTION: Primary: to perform high-dimensional flow cytometry on peripheral blood of patients with recurrent glioblastoma receiving standard of care anti-VEGF therapy with bevacizumab to understand the immune impact of the drug on various immune cell populations. Secondary: To perform an evaluation of ex vivo cytokine production in peripheral blood T …
This open-label, single arm clinical study is being conducted to assess the long-term safety and efficacy of aducanumab in participants with Alzheimer's disease who were actively participating in Aducanumab clinical studies 103, 205, 301, or 302 (aducanumab feeder studies) as of March 21st 2019. Participants who participated in 221AD302 will …
The overall objectives of this study are to evaluate feasibility and safety of thoracic duct sampling, including "in-and-out" cannulation and "indwelling" catheterization in early MS and to compare cellular and signaling markers in thoracic duct lymph compared to measures in the blood, within and across populations of MS patients before …
To compare the effect of mitapivat versus placebo on transfusion burden in subjects with alpha- or beta-transfusiondependent thalassemia (TDT) Transfusion reduction response (TRR), defined as a 50% reduction in transfused red blood cell (RBC) units with a reduction of greater that or equal to 2 units of transfused RBCs in …
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
Primary Objectives Cohort 1: To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when administered with cemiplimab among recurrent malignant glioma participants. Cohort 2: To determine if neoadjuvant immune checkpoint blockade (ICB) with ASP8374, cemiplimab and the combination of ASP8374 plus cemiplimab will induce …
1) To evaluate the effect of paltusotine versus placebo on IGF-1(Insulin-like growth factor) response 2) To evaluate the effect of paltusotine versus placebo on IGF-1 level 3) To evaluate the effect of paltusotine versus placebo on GH (growth hormone) response 4) To evaluate the effect of paltusotine versus placebo on …
PURPOSE: The overall purpose of the study is to assess the procedural safety profile and clinical efficacy outcomes of an imaging substrate-aided ventricular tachycardia (VT) ablation strategy that avoids general anesthesia, limits inductions, and reduces time devoted to substrate mapping in heart failure patients with severe left ventricular dysfunction. Primary …
The primary objective of this study is to investigate the superiority of chronic LBBAP compared to traditional right ventricular (RV) septal pacing in patients with high-degree conduction disease after transcatheter aortic valve replacement (TAVR). All patients enrolled in this study, have undergone TAVR within 2 weeks, developed high-grade conduction disease, …
This patisiran expanded access protocol (EAP) is an open-label, multicenter, single-arm study designed to provide pre-approval access to investigational patisiran for patients with ATTR amyloidosis with cardiomyopathy who, at baseline, have an inadequate response to or cannot tolerate standard of care. An intravenous infusion of study drug (patisiran 0.3 mg/kg) …
Please choose between Voice or SMS based delivery of verification code
or